No. you are referring to April 3 blog. The blogger changed his mind and raised the target to $30.
"... Our price target is $30 per share. Selling the HIV royalty, guidance that the FDA will accept the PROVE-3 study as part of the registration program, or the potential for lower cash burn rates in 2009 and 2010 are all things that could keep the shares moving higher."